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The Zucker diabetic fatty (ZDF) rat is a model of type II diabetes and metabolic syndrome based on impaired 
glucose tolerance caused by the inherited insulin-resistance gene. The ZDF rat exhibits progressive nephropathy; 
however, the detailed mechanisms have remained unclear. This study was performed to examine the possible 
involvement of enhanced intrarenal angiotensinogen in the development of renal injury in ZDF rats. Genetic 
pairs of male ZDF rats and control lean rats (N=6 each) were maintained from 12 to 17 weeks of age. At 17 weeks 
of age, fasting blood glucose and urinary 8-isoprostane levels were significantly higher in ZDF rats compared 
with the controls. Systolic blood pressure progressively increased in ZDF rats from 120+/-1 to 137+/-1 mmHg 
during this period. In contrast, systolic blood pressure did not increase in the controls. Kidney angiotensinogen 
protein levels were significantly increased in ZDF rats compared with the controls (1.83+/-0.34 vs. 1.00+/-0.17, 
relative ratio). Expression of angiotensin II type 1a receptor mRNA was similar between these groups. The 
measured indices of renal damage in the present study (glomerular sclerosis, interstitial expansion, glomerular 
macrophage infiltration, and renal arterial proliferation) were not significantly increased at this stage in ZDF 
rats. However, we previously showed that the increased reactive oxygen species-related angiotensinogen 
enhancement plays an important role in the development of renal injury in a genetic salt-sensitive hypertension. 
Thus, the present data suggest that elevated reactive oxygen species and reactive oxygen species-associated 
augmentation of intrarenal angiotensinogen may initiate the development of renal injury in ZDF rats. 
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1.  Introduction 
Diabetic nephropathy is the most common cause 
of end-stage renal failure in patients starting dialysis 
in developed countries [1]. Clinical trials have 
demonstrated that high glucose levels are the 
principal cause of renal damage in both type I [2] and 
type II diabetes [3]. The mechanisms underlying the 
development of diabetic nephropathy are extremely 
complex; however, activation of the intrarenal 
renin-angiotensin (Ang) system (RAS) has been 
suggested [4-10]. 
Angiotensinogen is the only known substrate for 
the enzyme, renin, which cleaves angiotensinogen to 
release a biologically inactive decapeptide, AngI [11]. 
Angiotensin-converting enzyme (ACE) cleaves a 
dipeptide from AngI to produce a biologically active 
peptide, AngII [11]. AngII stimulates aldosterone 
secretion, cell proliferation and migration [12], 
thrombosis [13], and superoxide production [14-16]. 
All of these factors are involved in development and 
progression of nephropathy. Our previous reports 
suggest that AngII stimulates angiotensinogen 
synthesis and that enhancement of angiotensinogen 
may be a key component in the maintenance of 
elevated circulating and intrarenal AngII levels 
[17-21]. 
High glucose generates reactive oxygen species 
(ROS) as a result of glucose auto-oxidation, 
metabolism, and formation of advanced glycosylation 
end products [22]. AngII also stimulates ROS 
generation [23]. ROS is one of the important mediators 
of vascular complications in diabetes [4, 22]. In 
addition, we previously showed that angiotensinogen 
expression is augmented by ROS in salt-sensitive 
hypertensive rats [24]. 
The Zucker diabetic fatty (ZDF) rat is considered 
to be an excellent animal model of type II diabetes that 
presents a physiological and metabolic profile similar 
t o  t h a t  s e e n  i n  h u m a n s  [ 2 5 ,  2 6 ] .  T h e  Z D F  r a t  i s  
characterized by hyperglycemia, hyperinsulinemia, 
hyperlipidemia, moderate hypertension, moderate 
obesity, and progressive renal injury [27, 28]. Schafer 
et al. [29] showed that ZDF rats established diabetes at 
17 weeks of age. Coimbra et al. [30] showed that ZDF 
rats developed focal and segmental sclerosis at 18 
weeks of age, although severe hyperlipidemia, 
hyperglycemia, and obesity predated it. Hoshi et al. 
[25] reported that ZDF rats showed 
glomeruloscrerosis as early as 20 weeks of age. 
Chander et al. showed that ZDF rats developed focal 
and segmental sclerosis at 22 weeks of age [31]. Thus, 
there are clear data demonstrating that ZDF rats show 
renal injury starting at 18-20 weeks of age. Although 
ZDF rats steadily show renal injury around 20 weeks 
of age, early initiation factors involved in the 
development of renal injury has not been elucidated 
in ZDF rats. Mizuno et al. [26] demonstrated that a 
pharmacological blockade of the RAS with AngII type 
1 (AT1) receptor blocker (ARB) reduced proteinuria Int. J. Biol. Sci. 2007, 3  41
and delayed the progression of renal disease 
independently from blood pressure control in ZDF 
rats. This result has suggested that the activated 
intrarenal RAS plays an important role in the 
development of renal injury in ZDF rats. Moreover, in 
salt sensitive hypertensive rats, we previously 
reported that the ROS-related activation of intrarenal 
angiotensinogen plays important roles in the 
development of renal injury [24]. These data 
prompted us to examine the possible involvement of 
enhanced ROS-associated augmentation of intrarenal 
angiotensinogen in the development of nephropathy 
at the early stage of diabetes in ZDF rats. Therefore, 
we have focused on intrarenal parameters of ZDF rats 
before the elicitation of renal injury. 
2.  Materials and Methods 
Animals 
The experimental protocol was approved by the 
Animal Care and Use Committee of Tulane University. 
Male ZDF rats (ZDF-fa/fa, 12 weeks of age, N=6) and 
age-matched control male lean rats (ZDF-+/?, 12 
weeks of age, N=6) were purchased from Charles 
River Laboratories. These rats were maintained from 
12 to 17 weeks of age. Rats were housed in metabolic 
cages and maintained in a temperature-controlled 
room regulated on a twelve-hour light/dark cycle 
with free access to water. Rats were fed with a 
commercially available rat chow containing normal 
salt and 16.7 kcal% fat (Formulab Diet 5008, LabDiet). 
Fasting blood glucose levels were measured using a 
glucose analyzer (TheraSense). Systolic blood 
pressures were measured by tail cuff 
plethysmography once a week as previously 
described [17-21, 32]. 
Urinary Measurements 
Twenty-four hour urine samples were collected 
once a week in centrifuge tubes containing 10 µg/ml 
of indomethacin and 0.005% butylated 
hydroxytoluene. Urine samples were centrifuged and 
the supernatant was separated and stored at –80°C 
until assayed for total protein and 8-isoprostane. 
Urinary concentration of total protein was measured 
by colorimetric assays using a commercially available 
kit (Bio-Rad). 8-isoprostane is the major urinary 
metabolite of F2-isoprostanes and is formed 
non-enzymatically from the action of superoxide 
radicals on arachidonic acid [33]. The urinary 
8-isoprostane excretions were measured by ELISA 
using a commercially available kit (Cayman). 
Sample Collections 
Blood and kidney samples were harvested at 17 
weeks of age. After decapitation, trunk blood was 
collected into chilled tubes containing 5 mmol/l 
EDTA, 20 µmol/l enalaprilat, 10 µmol/l pepstatin A, 
and 1.25 mmol/l 1,10-phenanthroline. Plasma was 
separated and stored at –20°C until assayed for 
plasma AngII by radioimmunoassay as previously 
described [17-21, 32]. Immediately after removal, one 
kidney was homogenized in cold methanol and renal 
AngII was measured by radioimmunoassay as 
previously described [17-21, 32]. The contralateral 
kidneys were separated into three pieces and 
snap-frozen in liquid nitrogen for protein extraction, 
immersed in RNAlater (Ambion) for total RNA 
extraction and immersed in zinc-saturated formalin 
(Anatech) for tissue fixation. 
Western Blot Analysis 
Protein extraction of renal cortex and Western 
blot analysis for angiotensinogen were performed as 
previously described [17-21, 32].  Sheep polyclonal 
antibody against purified rat angiotensinogen was 
produced and characterized at University of 
Queensland, Australia [34]. Anti beta-actin antibody 
was purchased from Sigma. Data of Western blot 
analysis for angiotensinogen protein levels were 
normalized by beta-actin protein levels. 
Quantitative Real-time RT-PCR 
Total RNA extraction of renal cortex and 
quantitative real-time RT-PCR for AT1a receptor were 
performed as previously described [32]. The 
information of sequences are as follows: AT1a 
receptor; forward primer, 5’-CTT GTT CCC TTT CCT 
TAT CA-3’, reverse primer, 5’-CGT TTC TTG GTT 
TGT TCT TT -3’, probe, 5’- CAC CAG CTA TAC CCT 
TAT TTG GAA AGC -3’; GAPDH, forward primer, 5’- 
CAG AAC ATC ATC CCT GCA TC -3’, reverse primer, 
5’- CTG CTT CAC CAC CTT CTT GA -3’, probe, 5’- 
CCT GGA GAA ACC TGC CAA GTA TGA TGA -3’. 
Data of quantitative RT-PCR for AT1a mRNA levels 
were normalized by GAPDH mRNA levels. 
Histological Analysis 
Histological samples were embedded in paraffin 
by an out-sourcing company (Mass Histology). The 
extent of glomerular sclerosis was evaluated with 
periodic acid Schiff-stained sections. The extent of 
interstitial expansion was evaluated with Picro-Sirius 
red-stained sections. Quantification was performed 
semi-automatically in a blind manner by using the 
Image-Pro plus software (Media Cybernetics) as 
previously described [32]. 
Immunohistochemistry 
Paraffin-embedded sections from the rat kidneys 
were also used for immunohistochemical analysis 
with the ABC method (Vector Laboratories). The 
numbers of monocytes/macrophages in glomeruli 
were examined by immunohistochemistry using a 
commercially available antibody against CD68 (ED-1, 
Serotec) as previously described [32]. The magnitude 
of arterial proliferation of afferent arteriolar walls was 
evaluated by immunohistochemistry using a 
commercially available antibody against 
alpha-smooth muscle isoform of actin (Dako) with 
elastin stain (Sigma) as previously described [32]. 
Statistical Analysis 
Statistical analysis was performed using paired 
or unpaired t-test. All data are presented as 
mean+/-SEM. p<0.05 was considered significant. 
3.  Results 
General Animal Data 
The rats’ profiles of body weight, fasting blood 
glucose, urine volume and urine protein excretion at 
17 weeks of age are shown in Table 1. The ZDF rats 
developed diabetes mellitus, as manifested by 
increases in water intake (ZDF rats: 66+/-17 ml/day Int. J. Biol. Sci. 2007, 3  42
vs. control lean rats: 29+/-6 ml/day at 17 weeks of 
age), urine volume, and blood glucose. The fasting 
glucose levels were significantly increased in ZDF rats 
compared to control lean rats. Urine volume and 
protein excretion also increased in ZDF rats compared 
to control lean rats. 
Table 1.  Characteristics of ZDF rats and control lean rats at 
17 weeks of age 
  Lean ZDF 
Body Weight, g  288 ± 7  378 ± 18* 
Fasting Blood Glucose, mg/dl  47 ± 5  148 ± 36** 
Urine Volume, ml/day  9.8 ± 1.0  44.3 ± 16.6* 
Urine Protein, mg/day  6.8 ± 0.6  22.1 ± 2.7** 
**p<0.01, *p<0.05 
Systolic Blood Pressure 
Systolic blood pressure was similar between ZDF 
and control lean rats at 12 weeks of age. ZDF rats 
showed a moderate increase in systolic blood pressure, 
which reached a significant level by 15 weeks of age 
(137+/-1 mmHg) compared with 12 weeks of age 
(120+/-1 mmHg). The control lean rats did not have 
increased blood pressures. 
Urinary 8-Isoprostane 
As shown in Figure 1, urinary 8-isoprostane 
excretion rates were not different between ZDF and 
control lean rats at 12 weeks of age. At 15 weeks of age, 
the urinary 8-isoprostane excretions showed a 
tendency to increase in ZDF rats and were 
significantly increased at 17 weeks of age. 
Kidney Angiotensinogen Protein 
As shown in Figure 2, angiotensinogen protein 
expression was increased in ZDF rats at 17 weeks of 
age. No differences in the amount of beta-actin were 
observed among samples. 
Figure 1.  The urinary 8-isoprostane excretions of ZDF and 
control lean rats.  The urinary 8-isoprostane was 
significantly augmented in ZDF rats at 17 weeks of age.  
**p<0.01 vs. control lean rats at the same age. 
 
 
Figure 2.  Kidney angiotensinogen levels in ZDF and control lean rats at 17 weeks of age.  (A) A representative Western blot 
analysis of angiotensinogen and beta-actin.  (B) The densitometric analysis shows that ZDF rats had significantly increased 
kidney angiotensinogen levels compared to control lean rats.  *p<0.05 vs. control lean rats at the same age. 
 
Plasma AngII, Kidney AngII and AT1a Receptor mRNA 
As shown in Figure 3, ZDF rats showed slightly 
increased plasma AngII concentrations. Similar to 
plasma concentrations, intrarenal AngII contents were 
also slightly increased in ZDF rats. However, plasma 
AngII concentrations and kidney AngII contents were 
not significantly increased in ZDF rats. As shown in 
Figure 4, AT1a receptor mRNA was not different 
between ZDF and control lean rats. Int. J. Biol. Sci. 2007, 3  43
Renal Damage 
Glomerular sclerotic index were not different 
between ZDF and control lean rats (Figure 5A-5C). 
Interstitial expansive index showed similar levels 
between ZDF and control lean rats (Figure 5D). 
Glomerular macrophage infiltration was not 
significantly increased in ZDF rats (Figure 5E). 
Afferent arteriolar wall thickness was not altered in 
ZDF compared to control lean rats (Figure 5F). 
Figure 3.  Plasma (A) and kidney (B) AngII levels in ZDF and control lean rats at 17 weeks of age.  Plasma AngII 
concentrations and kidney AngII contents were not significantly different between ZDF and control lean rats. 
 
Figure 4.  Kidney AT1a receptor mRNA in ZDF and control lean rats at 17 weeks of age.  Kidney AT1a receptor mRNA in 
ZDF were not significantly different compared with control lean rats. 
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Figure 5.  Evaluation of renal damage in ZDF and control lean rats at 17 weeks of age.  Renal damages were evaluated based 
on these four parameters: (A-C) glomerular sclerosis index using periodic acid-Schiff stained sections of ZDF (A) and 
control lean (B) rats, (D) interstitial expansion index using by Picro-Sirius red-stained sections, (E) glomerular macrophage 
 
4.  Discussion 
In this study, emphasis was placed on evaluating 
early mediators of renal damage in ZDF rats at 17 
weeks of age. Schafer et al. [29] showed that ZDF rats 
established diabetes at 17 weeks of age. Coimbra et al. 
[30] showed that ZDF rats developed focal and 
segmental sclerosis at 18 weeks of age, although 
severe hyperlipidemia, hyperglycemia, and obesity 
predated it. Hoshi et al. [25] reported that ZDF rats 
showed glomeruloscrerosis as early as 20 weeks of age. 
Chander et al. showed that ZDF rats developed focal 
and segmental sclerosis at 22 weeks of age [31]. Thus, 
there are clear data demonstrating that ZDF rats show 
renal injury starting at 18-20 weeks of age, and in the 
present study, ZDF rats at 17 weeks of age without 
nephropathy were examined whether augmented 
intrarenal angiotensinogen is involved in the 
development of renal injury. We observed that these 
ZDF rats show the angiotensinogen augmentation 
before the development of renal injury at 17 weeks of 
age in this study. 
In the present study, we have investigated the 
possible involvement of the enhanced 
angiotensinogen in renal injury in ZDF rats. At 17 
weeks of age, although ZDF rats were confirmed 
having high glucose concentration and urine protein, Int. J. Biol. Sci. 2007, 3  45
renal damage were not documented by glomerular 
sclerosis, interstitial expansion, glomerular 
macrophage infiltration or renal arterial proliferation. 
Importantly, the oxidative stress and intrarenal 
angiotensinogen were augmented at this time-point. 
Therefore, the augmentation of oxidative stress and 
intrarenal angiotensinogen are precedent to renal 
damage in ZDF rats. 
Recent studies have provided evidence that 
AngII stimulates intracellular formation of ROS [35, 
36]. AngII-induced ROS plays a pivotal role in several 
pathophysiological conditions such as hypertension, 
endothelial dysfunction, nitrate tolerance, 
atherosclerosis, and cellular remodeling [37]. 
Although plasma and kidney AngII levels were not 
significantly increased in ZDF rats, an oxidative stress 
marker, 8-isoprostane was significantly elevated in 
ZDF rats at 17 weeks of age. High glucose induces 
ROS generation via non-enzymatic glycation of 
proteins or glucose auto-oxidation [22]. 
Hyperglycemia, the main determinant of the initiation 
and progression of renal injury, not only generates 
more reactive oxygen metabolites, but also attenuates 
anti-oxidative mechanisms through non-enzymatic 
glycosylation of anti-oxidant enzymes [38]. It has been 
reported that 8-isoprostane is enhanced in the setting 
of diabetes in type I [39] and type II diabetic patients 
[40]. These studies support the concept that high 
glucose-induced ROS is involved in the setting of 
renal injury. 
Changes in angiotensinogen levels can control 
the activity of the RAS, and its up-regulation may lead 
to elevated AngII levels and increases in blood 
pressure [41]. Our previous report suggested that 
stimulation of angiotensinogen synthesis by AngII 
may be a key component in the maintenance of 
elevated intrarenal AngII levels [17]. We also reported 
that angiotensinogen expression is elevated 
independently from blood pressure in 
AngII-dependent hypertension [20, 21]. Although 
plasma and kidney AngII levels were not significantly 
increased in the present study, kidney 
angiotensinogen protein was increased in ZDF rats. 
Systolic blood pressure in ZDF rats was also 
significantly higher than in control lean rats, but this 
elevation did not reach a hypertensive range. 
Interestingly, it is reported that angiotensinogen gene 
expression is induced by high glucose in proximal 
tubular cells [42]. In addition, Hsieh et al. [43] 
demonstrated that the stimulatory action of high 
glucose on angiotensinogen gene expression in 
immortalized renal proximal tubular cells is mediated 
at least in part via ROS generation. We also showed 
that augmentation of angiotensinogen is caused by 
ROS in hypertensive rats [24]. Our present data also 
demonstrate concomitant increases of ROS and 
angiotensinogen in ZDF rats compared with control 
lean rats before renal injury in ZDF rats was evident. 
Our present study thus suggests that ROS and 
ROS-mediated angiotensinogen activation may have 
an important role in early mediation of renal injury in 
ZDF rats. 
We failed to demonstrate the enhanced levels of 
intrarenal AngII in ZDF rats even though the 
intrarenal AngII levels were maintained by the 
augmented levels of intrarenal angiotensinogen in 
ZDF rats. We did not measure plasma renin activity; 
however, it is well known that plasma renin activity is 
suppressed in both diabetic patients and animals 
[4-10]. The maintained levels of intrarenal AngII and 
the augmented levels of intrarenal angiotensinogen 
may partially account for the renoprotective effects of 
ARBs and ACE inhibitors in diabetic nephropathy 
even though the circulating RAS activity is 
suppressed in diabetes. 
Our present study may imply that ZDF rats 
treated with antioxidant may demonstrate favorable 
effects on renal levels of angiotensinogen and AngII as 
well as urinary protein excretion; however, the 
emphasis of the present study was to report that 
intrarenal oxidative stress and augmented 
angiotensinogen are precedent to renal injury in ZDF 
rats. Practically, it is very difficult to use specific and 
effective antioxidants in vivo study. Further in vivo 
and/or in vitro study may be required to clarify these 
issues. 
In summary, we have demonstrated in this study 
that the augmented oxidative stress and the enhanced 
intrarenal angiotensinogen precede the development 
of renal injury in ZDF rats. We previously reported 
that the ROS-related activation of intrarenal 
angiotensinogen plays important roles in the 
development of renal injury in salt sensitive 
hypertensive rats [24]. These data suggest that the 
augmented ROS and the ROS-associated activation of 
intrarenal angiotensinogen are involved in the 
development of renal injury. These mechanisms may 
partially account for the renoprotective effects of 
ARBs and ACE inhibitors in the diabetic nephropathy. 
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